10 recruiting, 9 completed, 3 terminated, 2 active not recruiting. 13 Phase 2, 12 Phase 1, 4 Phase 3, 1 Phase 4.
Follow Coherus Oncology, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases Dupilumab, Toripalimab - Metastatic Colorectal Cancer, Liver Metastases | Phase 1 / Phase 2 | Recruiting | Dan Feng | 24 | 2026-09-01 | 2026-08-12 |
| A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients NY-ESO-1 Peptide vaccine, Toripalimab-tpzi - Ovarian Cancer Stage IV, Ovarian Cancer Stage III | Phase 2 | Withdrawn | Georgetown University | 2026-09-01 | 2026-10-09 | |
| Window of Opportunity in Preserving Laryngeal Function Trial Toripalimab, Carboplatin, Cisplatin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Matthew Spector | 87 | 2026-04-06 | 2026-10-16 |
| PDT For Induction Therapy For Head And Neck Cancer Toripalimab-tpzi, Cisplatin, Docetaxel - Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 26 | 2026-03-09 | 2026-10-19 |
| Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation - Head and Neck Cancer, Squamous Cell Carcinoma | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 75 | 2026-02-18 | 2026-04-23 |
| Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC Nadunolimab, Toripalimab - Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Dan Feng | 24 | 2025-12-01 | 2026-02-19 |
| Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer Biopsy Procedure, Biospecimen Collection, Colonoscopy - Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 | Phase 2 | Recruiting | Emory University | 40 | 2025-09-19 | 2026-10-02 |
| Toripalimab With Chemotherapy for Sinus Cancer Toripalimab, Carboplatin, Docetaxel - Sinonasal Cancer, Paranasal Sinus Neoplasms | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 20 | 2025-06-17 | 2026-08-31 |
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas STC-15 in combination with toripalimab, STC-15 monotherapy - Solid Tumor, Sarcoma | Phase 1 / Phase 2 | Recruiting | STORM Therapeutics LTD | 107 | 2025-05-05 | 2026-10-22 |
| A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors CHS-114, Toripalimab, 5 Fluorouracil - Metastatic Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | Coherus Oncology, Inc. | 154 | 2025-04-01 | 2026-07-15 |
| A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors CHS-1000, Toripalimab - Advanced or Metastatic Solid Tumors | Phase 1 | Not yet recruiting | Coherus Oncology, Inc. | 48 | 2025-02-15 | 2024-09-19 |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma Casdozokitug, Toripalimab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | Coherus Oncology, Inc. | 72 | 2024-12-20 | 2026-07-15 |
| A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer Toripalimab, Cisplatin, Gemcitabine - Nasopharyngeal Cancer Recurrent | Phase 4 | Recruiting | Coherus Oncology, Inc. | 100 | 2024-11-01 | 2026-07-30 |
| Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors CHS-006 (anti-TIGIT), toripalimab (anti-PD-1) - Advanced Solid Tumor, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Coherus Oncology, Inc. | 22 | 2023-04-26 | 2025-05-01 |
| Study of CHS-114 in Participants With Advanced Solid Tumors CHS-114, toripalimab - Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | Phase 1 | Active not recruiting | Coherus Oncology, Inc. | 87 | 2022-12-15 | 2026-08-12 |
| Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma Casdozokitug, Atezolizumab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Terminated | Coherus Oncology, Inc. | 30 | 2022-04-12 | 2026-10-01 |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer SRF617, etrumadenant, zimberelimab - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 2 | Terminated | Coherus Oncology, Inc. | 16 | 2022-01-17 | 2025-05-08 |
| An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca Pegfilgrastim-Cbqv - Febrile Neutropenia, Non-myeloid Malignancy | Unknown | Coherus Oncology, Inc. | 200 | 2020-08-01 | 2020-12-23 | |
| Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors CHS-388, Pembrolizumab, Toripalimab - Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 | Completed | Coherus Oncology, Inc. | 145 | 2020-04-22 | 2026-07-15 |
Showing 20 of 28. Sign in to see all of them.
Neoplasms (7) · Carcinoma, Hepatocellular (4) · Carcinoma, Squamous Cell (3) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Liver Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Arthritis, Rheumatoid (2) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Squamous Cell Carcinoma (2) · Neoplasm Metastasis (2) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1)
toripalimab (15) · Cisplatin (6) · Carboplatin (4) · pegfilgrastim (4) · Docetaxel (3) · Albumin-Bound Paclitaxel (2) · Bevacizumab (2) · Etanercept (2) · Gemcitabine (2) · Radiotherapy (2) · pembrolizumab (2) · Adalimumab (1) · Biopsy (1) · CP protocol (1) · Chemoradiotherapy (1)
United States (25) · Canada (6) · Australia (3) · Israel (3) · Poland (3) · South Africa (3) · Taiwan (3) · Germany (2) · Japan (2) · Russia (2) · Singapore (2) · South Korea (2) · Belarus (1) · Bulgaria (1) · Chile (1)
Barbara Finck, MD (4) · Barbara K Finck, M.D. (2) · Dan Feng, MD, PhD (2) · Alison O'Neill, MD (1) · Barbara P Finck, M.D. (1) · Kartik Sehgal, MD (1) · Matthew Spector, MD, FACS (1) · Michael Gibson (1) · Nyall R London, MD, Ph.D (1) · Oluwadunni E. Emiloju, MBBS, MS (1) · Samir N Khleif, MD (1) · Sandra Tong, MD (1) · Sashi Naidu, MD (1) · Thomas Marron, MD, PhD (1)
PMID 35034311, PMID 41423415, PMID 32789809
P30CA138292 (1)